Skip to content
  • NEW! 2021 CATALOGS
  • NEWSROOM
    • Latest News
    • Publications
    • Press Releases
    • Videos
    • Posters
    • Conferences
  • CONTACT
    • General Inquiries
    • Customer Support
    • Technical Support
    • Global Distributor Support
  • LabPMM
    • LabPMM, LLC (USA)
    • LabPMM, GmbH (Germany)
    • LabPMM, GK (Japan)
  • MY ACCOUNT
    • Login
    • Create Account
Invivoscribe Logo Invivoscribe Logo Invivoscribe Logo
  • PRODUCTS
    • Products Overview

      Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.


      EXPLORE PRODUCTS ⟶
      SEARCH PRODUCT DOCUMENTS & IFUs ⟶
    • Next-Generation Sequencing
      • CE-IVD
        • Illumina®
        • Thermo Fisher®
      • RUO
        • Illumina®
        • Thermo Fisher®
      • MRD Clonality
    • Companion Diagnostics (CDx)
      • LeukoStrat® CDx FLT3
         Mutation Assay
      • CE-IVD
      • IVD (US)
      • IVD (JP)
    • ABI Fluorescence Detection
      • CE-IVD
        • Clonality
        • FLT3
      • RUO
        • Clonality
        • FLT3
        • Translocations
    • Gel Detection
      • CE-IVD
        • Clonality
        • FLT3
        • Translocations
      • RUO
        • Clonality
        • FLT3
        • Translocations
    • Controls
      • Master Mix Controls
      • DNA Controls
      • RNA Controls
      • MRD Controls
    • Reagents
      • ASRs
      • Enzymes
      • Hi-Di Formamide
    • NEW! 2021 Product Catalog
  • CLINICAL LAB SERVICES
    • Clinical Lab Services Overview

      The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

      EXPLORE SERVICES ⟶
    • NGS Cancer Panels
      • MyMRD
      • MyAML
      • MyHEME
    • MFC Panels
      • Hematolymphoid Screening Panel
      • AML MRD Assay
    • MRD NGS Tests
      • Clonality
      • FLT3 ITD
      • NPM1
    • Targeted Genes
      • FLT3
      • NPM1
    • Clonality NGS Tests
      • SHM
      • IGH
      • IGK
      • TRG
      • TRB
    • Companion Diagnostic (CDx) Tests
      • CDx – USA
      • CDx – Germany
      • CDx – Japan
    • CORONAVIRUS COVID-19 TESTING

      Performed with real-time reverse transcription polymerase chain reaction (RT-PCR) to detect nucleic acid from SARS-CoV-2.


      LEARN MORE ⟶
    • Custom Assays
    • NEW! 2021 Services Catalog
  • DISEASES
    • Lymphoid
      • Mature B-cell
      • Mature T-cell
    • Myeloid
      • Myelodysplastic Syndromes (MDS)
      • Acute Myeloid Leukemia (AML)
      • Myeloproliferative Neoplasms (MPNs)
    • Hematological Testing Menu

      Browse our comprehensive menu of product & testing services.

      EXPLORE MENU ⟶
  • PARTNERSHIPS
    • Partnerships Overview

      A proven strategy to accelerate
      drug approvals

      EXPLORE PARTNERSHIPS ⟶
    • Product Development

      Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

      EXPLORE ⟶
    • Manufacturing

      cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

      EXPLORE ⟶
    • LabPMM®

      Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

      EXPLORE ⟶
    • Global Regulatory Expertise

      Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

      EXPLORE ⟶
  • SCIENCE
    • Science Overview

      We take pride in expanding the science that bridges personalized medicine with quality healthcare.

      EXPLORE OUR SCIENCE ⟶
    • Personalized Medicine

      Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

      EXPLORE PERSONALIZED MEDICINE ⟶
  • PUBLICATIONS
    • Featured Publication

      November 17th, 2020
      Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

      VIEW PUBLICATION ⟶
    • Latest Publications

      November 17th, 2020
      Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

      VIEW PUBLICATION ⟶

      October 30th, 2020
      Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

      VIEW PUBLICATION ⟶
      VIEW ALL PUBLICATIONS ⟶
  • COMPANY
    • Company
      • About Us
      • Leadership Team
      • Board of Directors
      • Newsroom
      • Global Distributors
      • Licensure and Certifications
      • Search Career Openings
      • Shop Corporate Gear
    • Invivoscribe Locations
       
      Invivoscribe, Inc. (USA)
      San Diego, CA, US
      CONTACT US ⟶
       
      Invivoscribe Therapeutics, Inc. (USA)
      San Diego, CA, US
      CONTACT US ⟶
       
      Invivoscribe, SARL (France)
      La Ciotat, France
      CONTACT US ⟶
       
      Invivoscribe Diagnostic Technologies,(Shanghai) Co.,Ltd.
      Shanghai, China
      CONTACT US ⟶
    • LabPMM Locations
       
      LabPMM, LLC (USA)
      San Diego, CA, US
      CONTACT US ⟶
       
      LabPMM, GmbH (Germany)
      Martinsried, Germany
      CONTACT US ⟶
       
      LabPMM, GK (Japan)
      Kanagawa 210-0821, Japan
      CONTACT US ⟶
    • Support
       
      Invivoscribe, Inc. (USA)
      CONTACT US ⟶
       
      Invivoscribe, SARL (France)
      CONTACT US ⟶
       
      Invivoscribe Diagnostic Technologies,(Shanghai) Co.,Ltd.
      CONTACT US ⟶
       
      LabPMM, LLC (USA)
      CONTACT US ⟶
       
      LabPMM, GmbH (Germany)
      CONTACT US ⟶
       
      LabPMM, GK (Japan)
      CONTACT US ⟶
  • Search
    • Search Articles & Publications